Adaptive Biotechnologies (ADPT) Q1 2026 earnings review
MRD Engine Turns Highly Profitable, Masking Immune Medicine Collapse
Adaptive delivered a powerful Q1 2026, driven entirely by its Minimal Residual Disease (MRD) segment. MRD revenue surged 53% YoY to $67.1M, and segment Adjusted EBITDA flipped from a $4.1M loss a year ago to a $12.1M profit. This massive operating leverage helped cut the total company net loss by 33% to $20.0M. Management confidently raised FY26 MRD guidance. However, the Immune Medicine business is deteriorating rapidly—revenue collapsed 57% and its losses widened—creating a severe drag on an otherwise stellar clinical diagnostics growth story.
🐂 Bull Case
Test volume accelerated to 41% YoY growth (32,595 tests), proving that the transition to blood-based testing and community EMR integrations is deeply entrenching the product into standard oncology workflows.
The core MRD business is proving highly scalable. Stripping away the struggling Immune Medicine arm, the MRD segment alone generated an 18% Adjusted EBITDA margin this quarter, funding the majority of corporate overhead.
🐻 Bear Case
The Immune Medicine segment's revenue dropped 57% YoY to just $3.8M, while generating an Adjusted EBITDA loss of $10.4M. This segment is actively destroying the value created by the MRD business.
A massive $9.0M of Q1 revenue came from a single pharma regulatory milestone. Without this lumpy payment, core clinical growth metrics would look noticeably less explosive.
⚖️ Verdict: 🟢
Bullish. The underlying clinical diagnostic engine is hitting its stride. Profitability is scaling fast, and volume growth is accelerating. If management can effectively quarantine or spin off the cash-burning Immune Medicine segment, the true earnings power of Adaptive will be unlocked.
Key Themes
clonoSEQ Volume Growth is Accelerating
Test volumes hit a record 32,595, representing 41% YoY growth. This marks a structural acceleration from the 36-38% rates seen in early FY25. The shift toward blood-based testing and aggressive community oncology penetration via EMR networks are successfully lowering the friction for serial monitoring.
Pharma Regulatory Endpoints Yielding Cash
The company recognized $9.0M from its first U.S. primary endpoint milestone in the pharma segment. This validates the strategic bet to secure FDA ODAC endorsement for MRD as an endpoint in Multiple Myeloma, transitioning the pharma business from a pure sequencing service to a high-margin milestone generator.
Core MRD Revenue Decelerating Excluding Milestones
Headline MRD revenue grew an impressive 53% YoY. However, subtracting the lumpy $9.0M pharma regulatory milestone, core MRD revenue was $58.1M—representing roughly 33% YoY growth. This is a deceleration from the 45% ex-milestone growth rate seen in FY25, signaling that clinical Average Selling Price (ASP) gains might be cooling despite strong volume growth.
Immune Medicine Segment Drag
The strategic pivot away from internal therapeutics to data monetization is taking a severe toll. Segment revenue plunged 57% YoY (and 26% even excluding the defunct Genentech deal). The $10.4M Adjusted EBITDA loss from this segment completely wiped out the $12.1M profit generated by MRD, pushing the whole company back into the red.
NovaSeq X Plus and Flatiron EMR Tech Advancements
Specific technology rollouts are driving the bottom line. The implementation of Illumina's NovaSeq X Plus platform has fundamentally lowered sequencing costs, directly enabling the MRD segment's margin expansion. Concurrently, deep workflow integration into Flatiron's OncoEMR continues to automate serial testing, creating a defensive moat against new entrants.
Insulation from Macro and Tariff Pressures
Unlike life science tool peers exposed to NIH budget constraints and supply chain tariffs, Adaptive's shift to a clinical diagnostic focus insulates it from these macro pressures, providing a highly defensive growth profile in a volatile healthcare budget environment.
Other KPIs
Reversing positively. Total company net loss narrowed from $29.8M a year ago. Excluding the zero-revenue impact of the legacy Genentech agreement, the underlying core business cut its net loss by over $13M YoY, showcasing strong cost discipline against growing sales.
Stable. The company's cash position grew slightly from $227.0M at the end of FY25 (inclusive of Digital Biotechnologies cash). With cash burn rapidly approaching breakeven, dilution risk has effectively been eliminated.
Accelerating slightly. OpEx increased 10% YoY from $82.0M. While higher, this expense growth is vastly outpaced by the 35% growth in total revenue, confirming the business is scaling with robust operating leverage.
Guidance
Accelerating. Management raised the target from the previous $255M-$265M range. The new midpoint implies 24.5% YoY growth. Achieving $67.1M in Q1 already secures 25% of the high end of this guidance, making the raise look conservative.
Stable. The range implies virtually no change from the annualized run-rate of Q1 ($360M). This confirms management's commitment to holding the line on costs while letting clinical volume drive top-line expansion.
Key Questions
Immune Medicine Cash Burn Floor
With Immune Medicine revenue collapsing 57% YoY to just $3.8M, what is the absolute floor for segment cash burn before management considers structurally shutting down or spinning off these assets?
Core ASP vs Milestone Dependency
Q1 benefited from a $9M milestone payment. How much of the upgraded $260-$270M FY26 MRD revenue guidance relies on further lumpy milestone achievements versus sustainable expansion in clinical Average Selling Price (ASP)?
Margin Ceiling
With the NovaSeq X Plus platform fully operational, how much more sequencing gross margin expansion is structurally possible over the next four quarters?